Physician profile
Meredith Pham
NPI 1477176246
$9,471.37
in general payments reported to CMS, 2019-2025
28 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.22 · 2022: $1,368 · 2023: $2,556 · 2024: $3,812 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,902 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,902.48 |
| Education | $184.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,279.19 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $1,036.21 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,030.54 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $804.27 | 2023-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $709.22 | 2023-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.68 | 2023-2025 | Spevigo |
| Genzyme Corporation | $463.12 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $416.60 | 2024-2025 | |
| Galderma Laboratories, L.P. | $384.20 | 2023-2024 | Aklief, Twyneo, Oracea |
| Lilly USA, LLC | $345.09 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $320.51 | 2022-2025 | Ilumya, Blu-U, Odomzo |
| Arcutis Biotherapeutics, INC. | $269.79 | 2023 | |
| Incyte Corporation | $266.33 | 2023-2024 | Opzelura |
| Kerecis Limited | $263.66 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Janssen Biotech, INC. | $199.09 | 2024-2025 | Tremfya, Stelara, Simponi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $178.17 | 2022-2024 | |
| Avita Medical Americas, LLC | $173.59 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $143.33 | 2024 | Siliq, Duobrii, Cabtreo |
| Medline Industries LP | $118.42 | 2024 | Medline Industries, INC., Medline Industries, INC. |
| Pfizer INC. | $112.65 | 2024 | |
| Leo Pharma INC. | $110.78 | 2024 | Adbry |
| Polynovo North America LLC | $98.05 | 2024 | Novosorb Btm |
| Genentech USA, INC. | $61.55 | 2022-2024 | Xolair |
| Kyowa Kirin, INC. | $40.02 | 2022 | |
| Organon LLC | $34.31 | 2025 | Vtama |
| Almirall LLC | $33.47 | 2023 | Klisyri, Seysara |
| Stemline Therapeutics INC. | $24.47 | 2022 | |
| Krystal Biotech INC | $23.06 | 2025 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.